Bradley Canino
Stock Analyst at Stifel
(1.92)
# 1,539
Out of 4,412 analysts
64
Total ratings
34.55%
Success rate
-8.34%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Maintains: Buy | $120 → $130 | $93.10 | +39.63% | 5 | Apr 26, 2024 | |
| AFMD Affimed | Maintains: Hold | $1 → $5 | $5.49 | -8.93% | 4 | Apr 1, 2024 | |
| SMMT Summit Therapeutics | Initiates: Buy | $8 | $3.88 | +106.19% | 1 | Mar 26, 2024 | |
| ALXO ALX Oncology Holdings | Downgrades: Hold | $10 → $14 | $16.93 | -17.31% | 4 | Mar 8, 2024 | |
| MRUS Merus | Maintains: Buy | $40 → $65 | $45.11 | +44.09% | 5 | Feb 29, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $35 → $55 | $34.66 | +58.68% | 4 | Feb 23, 2024 | |
| CCCC C4 Therapeutics | Reiterates: Buy | $12 → $13 | $6.32 | +105.70% | 3 | Feb 23, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $25 → $30 | $6.59 | +355.24% | 3 | Feb 22, 2024 | |
| CELC Celcuity | Initiates: Buy | $40 | $16.05 | +149.22% | 1 | Feb 22, 2024 | |
| DCPH Deciphera Pharmaceuticals | Maintains: Buy | $22 → $23 | $25.28 | -9.02% | 5 | Feb 7, 2024 | |
| ARVN Arvinas | Maintains: Buy | $46 → $42 | $31.90 | +31.66% | 4 | Nov 8, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $44 → $36 | $11.42 | +215.24% | 15 | Nov 7, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $38 → $36 | $21.28 | +69.17% | 2 | Oct 26, 2023 | |
| NUVL Nuvalent | Reiterates: Buy | n/a | $67.95 | - | 2 | Oct 4, 2023 | |
| BDTX Black Diamond Therapeutics | Upgrades: Buy | $2 → $10 | $5.87 | +70.50% | 4 | Jun 30, 2023 | |
| KURA Kura Oncology | Maintains: Buy | $24 → $25 | $20.06 | +24.63% | 2 | Jun 12, 2023 |
Blueprint Medicines
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $93.10
Upside: +39.63%
Affimed
Apr 1, 2024
Maintains: Hold
Price Target: $1 → $5
Current: $5.49
Upside: -8.93%
Summit Therapeutics
Mar 26, 2024
Initiates: Buy
Price Target: $8
Current: $3.88
Upside: +106.19%
ALX Oncology Holdings
Mar 8, 2024
Downgrades: Hold
Price Target: $10 → $14
Current: $16.93
Upside: -17.31%
Merus
Feb 29, 2024
Maintains: Buy
Price Target: $40 → $65
Current: $45.11
Upside: +44.09%
Kymera Therapeutics
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $34.66
Upside: +58.68%
C4 Therapeutics
Feb 23, 2024
Reiterates: Buy
Price Target: $12 → $13
Current: $6.32
Upside: +105.70%
Relay Therapeutics
Feb 22, 2024
Maintains: Buy
Price Target: $25 → $30
Current: $6.59
Upside: +355.24%
Celcuity
Feb 22, 2024
Initiates: Buy
Price Target: $40
Current: $16.05
Upside: +149.22%
Deciphera Pharmaceuticals
Feb 7, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $25.28
Upside: -9.02%
Arvinas
Nov 8, 2023
Maintains: Buy
Price Target: $46 → $42
Current: $31.90
Upside: +31.66%
Zentalis Pharmaceuticals
Nov 7, 2023
Maintains: Buy
Price Target: $44 → $36
Current: $11.42
Upside: +215.24%
Syndax Pharmaceuticals
Oct 26, 2023
Maintains: Buy
Price Target: $38 → $36
Current: $21.28
Upside: +69.17%
Nuvalent
Oct 4, 2023
Reiterates: Buy
Price Target: n/a
Current: $67.95
Upside: -
Black Diamond Therapeutics
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $5.87
Upside: +70.50%
Kura Oncology
Jun 12, 2023
Maintains: Buy
Price Target: $24 → $25
Current: $20.06
Upside: +24.63%